NCT03844074 - A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

July 23, 2020

Study Completion Date

August 13, 2020

Conditions

Age-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration

Interventions

BIOLOGICAL

bevacizumab

1.25 mg, intravitreal injection

BIOLOGICAL

ranibizumab

0.5mg, intravitreal injection

Trial Locations (9)

Clinical Site, Hurstville

Clinical Site, Liverpool

Clinical Site, Sydney

Clinical Site, Westmead

Clinical Site, Brisbane

Clinical Site, Adelaide

Clinical Site, Hobart

Clinical Site, Essendon

Clinical Site, Glen Waverley